Stenzel K H, Whitsell J C, Stubenbord W T, Fotino M, Riggio R R, SULLIVAN J F, Lewy J E, Cheigh J S, Rubin A L
Ann Surg. 1974 Jul;180(1):29-34. doi: 10.1097/00000658-197407000-00005.
Patient and graft survival were reviewed in a series of 249 kidney transplants done from 1963 to March 1973. Patient survival was calculated by the life table method for the periods 1963-1970, and 1970-1973, since in 1970 a formal Kidney Center was established and mortality rates changed. Graft survival was analyzed in terms of donor source, HL-A matching and immune responsiveness to HL-A antigens. Three-year predicted mortality for cadaver kidney recipients was 62% between 1963 and 1969 (42 patients) and 8% between 1970 anid 1973 (67 patients). Similar predicted mortality for related living donors was 30% between 1963 and 1969 (52 patients) and 14% between 1970 and 1973 (85 patients). Mortality has continued to decrease and there has been only one death in the last 87 consecutive transplants, including 57 consecutive cadaver transplants. Oneyear predicted kidney survival for the 10-year period is 44% for cadaveric, 60% for non HL-A identical related living and 90% for HL-A identical sibling donors. In the cadaver group, those sharing 2 or more HL-A antigens had the same kidney survival as the non HL-A identical related living donor grafts. Since cadaver graft recipients are on dialysis for a longer period of time, immune responsiveness can be detected by their response to blood transfusions, whereas this determination could not be made in our related living donor group. Non-responsive cadaver kidney recipients had 80% one year kidney survival. We conclude that transplant mortality can be reduced to less than 10% by the Center approach to treatment of renal disease, dialysis does not adversely affect future transplantation, and excellent (80%) kidney survival can be expected in properly selected cadaver graft recipients.
回顾了1963年至1973年3月期间进行的249例肾移植患者的存活情况及移植物存活情况。1963 - 1970年以及1970 - 1973年期间,采用寿命表法计算患者存活率,因为1970年设立了正规的肾脏中心,死亡率发生了变化。从供体来源、HL - A配型以及对HL - A抗原的免疫反应性方面分析移植物存活情况。1963年至1969年期间(42例患者),尸体肾受者的三年预测死亡率为62%,1970年至1973年期间(67例患者)为8%。1963年至1969年期间(52例患者),亲属活体供者的类似预测死亡率为30%,1970年至1973年期间(85例患者)为14%。死亡率持续下降,在最近连续的87例移植手术中,仅1例死亡,其中包括57例连续的尸体肾移植。在这10年期间,尸体肾移植1年的预测肾存活率为44%,非HL - A配型相同的亲属活体供者为60%,HL - A配型相同的同胞供者为90%。在尸体肾组中,共享2个或更多HL - A抗原的患者的肾存活率与非HL - A配型相同的亲属活体供者移植物的存活率相同。由于尸体肾移植受者接受透析的时间更长,可通过他们对输血的反应检测免疫反应性,而在我们的亲属活体供者组中无法进行这种测定。无反应的尸体肾受者1年肾存活率为80%。我们得出结论,通过肾脏疾病治疗的中心方法,移植死亡率可降至10%以下,透析不会对未来移植产生不利影响,并且在适当选择的尸体肾移植受者中,可预期有出色的(80%)肾存活率。